Abstract
Objective Pyrotinib, a novel oral irreversible dual pan-ErbB tyrosine kinase inhibitor (TKI), has been approved in China for the treatment of HER2-positive advanced or metastatic breast cancer. This study aimed to conduct a population pharmacokinetics (PK) analysis of pyrotinib and to evaluate the impact of certain HER2-positive breast cancer patient characteristics on pyrotinib’s PK.
Method A total of 1152 samples, provided by 59 adult female patients from two phase I clinical trials, were analyzed by nonlinear mixed-effects modeling. Monte Carlo simulation was conducted to assess the impact of covariates following exposure to pyrotinib.
Results The PK of pyrotinib was adequately described by a one-compartment model with first-order absorption and elimination. Patient’s age and total protein levels can affect pyrotinib’s apparent volume of distribution, and concomitant use of montmorillonite powder had significant effects on the bioavailability of pyrotinib. No PK interactions were observed between capecitabine and pyrotinib.
Conclusion In this study, a population PK model of pyrotinib was developed to determine the influence of patient characteristics on the PK of pyrotinib. While patient age and total protein levels can significantly affect the apparent distribution volume of pyrotinib, the magnitude of the impact was limited, thus no dosage adjustment was recommended. Furthermore, concomitant use of montmorillonite powder for diarrhea can decrease the bioavailability of pyrotinib by 50.3%.
Competing Interest Statement
This study was funded by Jiangsu Hengrui Medicine Co. Ltd. Da Xu, Kai-jing Zhao are employees of Jiangsu Hengrui Medicine Co. Ltd.
Clinical Trial
NCT01937689;NCT02361112
Funding Statement
This study was funded by Jiangsu Hengrui Medicine Co. Ltd. Da Xu, Kai-jing Zhao are employees of Jiangsu Hengrui Medicine Co. Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Both studies were conducted in accordance with the principles of the Declaration of Helsinki (October 2013) and the International Conference on Harmonization Guidelines for Good Clinical Practice. Study protocols were approved by the ethics committee at each trial center. Informed consent was obtained from each participant included in each study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.
Abbreviations
- ALT
- alanine aminotransferase
- AST
- aspartate aminotransferase
- AUC
- concentration-time curve
- BMI
- body mass index
- BSV
- between-subject variability
- BW
- body weight
- CL/F
- apparent clearance
- CYP
- cytochrome P450
- CWRES
- conditional weighted residual error
- eGFR
- estimated glomerular filtration rate
- GOF
- goodness-of-fit
- HER
- human epidermal growth factor receptor
- ka
- absorption rate constant
- LLOQ
- lower limit of quantitation
- pcVPC
- prediction corrected visual prediction check
- popPK
- population PK
- PK
- pharmacokinetics
- RUV
- residual unexplained variability
- SCr
- serum creatinine
- TB
- total bilirubin
- TKI
- tyrosine kinase inhibitors
- TP
- total protein
- Vd/F
- apparent volume of distribution
